Manufacturer: Pharmacia & Upjohn (Pfizer)
Brand Name: Aromasin
Aromasin (Exemestane) 25 mg 30 pills
Item price: $2.80
Peculiarities of use Before starting treatment with aromatase inhibitors, it is necessary to evaluate the levels of 25-hydroxy vitamin D in the body, since often there is a severe deficiency associated with early stages of breast cancer. Vitamin D-deficient women need to get extra vitamin D.
Given the mechanism of action, Aromasin should not be prescribed to women with premenopausal endocrine status. Therefore, in acceptable clinical cases, it is necessary to establish postmenopausal status by assessing the levels of LH, FSH and estradiol. Given that Aromasin is a drug that greatly reduces estrogen levels, a decrease in bone mineral density can be expected.
For adjuvant therapy with the drug for women suffering from osteoporosis or there is a risk of its occurrence, it is necessary to evaluate the parameters of bone mineral density using densitometry at the beginning of treatment. Patients who use Aromasin should be monitored, and if necessary, start therapy for osteoporosis.
Aromasin tablets contain sucrose; they cannot be prescribed to patients with rare congenital defects in fructose metabolism, glucose and galactose malabsorption, or sucrose isomaltase deficiency. Aromasin tablets contain methyl paraben, which can cause allergic reactions (possibly delayed).
Adults and elderly patients Aromasin is recommended to take 25 mg once a day daily, preferably after meals.
In patients with early-stage breast cancer, treatment with Aromasin should be continued until five years of sequential adjuvant hormone therapy (continued Aromasin therapy after tamoxifen) is completed or the tumor recurs.
In patients with advanced breast cancer, Aromasin treatment should be continued until tumor progression is evident.
Overdose Data on the use of Aromasin in single doses of 600-800 mg indicate good tolerance to these doses. A dose of Aromasin, which can lead to life-threatening symptoms, has not been established.
In animal experiments, mortality was recorded after administration of a single dose equivalent to 2000 and 4000 recommended human doses in mg / m 2, respectively. There are no specific antidotes for overdose; symptomatic treatment should be given. Adverse Reactions Aromasin was generally well tolerated in all studies when a dose of 25 mg / day was used, adverse events were usually mild to moderate.
The frequency of treatment interruptions through adverse events was 7.4% in patients with early stage breast cancer who received Aromasin treatment after starting adjuvant tamoxifen therapy. The most common adverse events were hot flashes (22%), arthralgia (18%), and increased fatigue (16%).